This mechanism might be most relevant for the use of DCexos as cancer vaccines, as studies have shown that only OVA protein-loaded but not peptide-loaded DCexos induced strong (allogeneic) CD8 T cell responses without requiring exosomal MHCI in vivo [65,66]. The gene discussed is CD8A; the disease is cancer.